Biotech firm Immunocore, which traces its roots to Oxford spin-out Avidex, has signed a pre-clinical milestone payment deal with pharmaceutical giant GlaxoSmithKline (GSK) worth £142m ($212m) to develop the next-generation of cancer-fighting drugs. In addition, GSK will pay up to £200m ($300m) in development and commercial milestone payments for each product that reaches the market.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
